Robert Schnoll1, Frank Leone2, Anna Veluz-Wilkins3, Andrew Miele1, Anita Hole1, Nancy C Jao3, E Paul Wileyto4, Allison J Carroll3, Ravi Kalhan3,5, Jyoti Patel6, Corey Langer7, Su Fen Lubitz1, Brian Hitsman8. 1. Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Preventive Medicine, Northwestern University, Chicago, Illinois. 4. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Department of Medicine, Northwestern University, Chicago, Illinois. 6. Department of Medicine, University of Chicago, Chicago, Illinois. 7. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 8. Department of Preventive Medicine, Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
Abstract
OBJECTIVE: Continuing to smoke after a cancer diagnosis undermines prognosis. Yet few trials have tested Food and Drug Administration (FDA)-approved tobacco use medications in this population. Extended use varenicline may represent an effective treatment for cancer patients who smoke given barriers to cessation including a prolonged time line for relapse. METHODS: A placebo-controlled randomized trial tested 12 weeks of varenicline plus 12 weeks of placebo (standard [ST]) vs 24 weeks of varenicline (extended [ET]) with seven counseling sessions for treatment-seeking cancer patients who smoke (N = 207). Primary outcomes were 7-day biochemically confirmed abstinence at weeks 24 and 52. Treatment adherence and side effects, adverse and serious adverse events, and blood pressure were assessed. RESULTS:Point prevalence and continuous abstinence quit rates at weeks 24 and 52 were not significantly different across treatment arms (P's > 0.05). Adherence (43% of sample) significantly interacted with treatment arm for week 24 point prevalence (odds ratio [OR] = 2.31; 95% confidence interval [CI], 1.15-4.63; P = 0.02) and continuous (OR = 5.82; 95% CI, 2.66-12.71; P < 0.001) abstinence. For both outcomes, adherent participants who received ET reported higher abstinence (60.5% and 44.2%) vs ST (44.7% and 27.7%), but differences in quit rates between arms were not significant for nonadherent participants (ET: 9.7% and 4.8%; ST: 12.7% and 10.9%). There were no significant differences between treatment arms on side effects, adverse and serious adverse events, and rates of high blood pressure (P's > 0.05). CONCLUSIONS: Compared with ST, ET varenicline does not increase patient risk and increases smoking cessation rates among patients who adhere to treatment. Studies are needed to identify effective methods to increase medication adherence to treat patient tobacco use effectively.
RCT Entities:
OBJECTIVE: Continuing to smoke after a cancer diagnosis undermines prognosis. Yet few trials have tested Food and Drug Administration (FDA)-approved tobacco use medications in this population. Extended use varenicline may represent an effective treatment for cancerpatients who smoke given barriers to cessation including a prolonged time line for relapse. METHODS: A placebo-controlled randomized trial tested 12 weeks of varenicline plus 12 weeks of placebo (standard [ST]) vs 24 weeks of varenicline (extended [ET]) with seven counseling sessions for treatment-seeking cancerpatients who smoke (N = 207). Primary outcomes were 7-day biochemically confirmed abstinence at weeks 24 and 52. Treatment adherence and side effects, adverse and serious adverse events, and blood pressure were assessed. RESULTS: Point prevalence and continuous abstinence quit rates at weeks 24 and 52 were not significantly different across treatment arms (P's > 0.05). Adherence (43% of sample) significantly interacted with treatment arm for week 24 point prevalence (odds ratio [OR] = 2.31; 95% confidence interval [CI], 1.15-4.63; P = 0.02) and continuous (OR = 5.82; 95% CI, 2.66-12.71; P < 0.001) abstinence. For both outcomes, adherent participants who received ET reported higher abstinence (60.5% and 44.2%) vs ST (44.7% and 27.7%), but differences in quit rates between arms were not significant for nonadherent participants (ET: 9.7% and 4.8%; ST: 12.7% and 10.9%). There were no significant differences between treatment arms on side effects, adverse and serious adverse events, and rates of high blood pressure (P's > 0.05). CONCLUSIONS: Compared with ST, ET varenicline does not increase patient risk and increases smoking cessation rates among patients who adhere to treatment. Studies are needed to identify effective methods to increase medication adherence to treat patienttobacco use effectively.
Authors: Grace Crawford; Jessica Weisbrot; Joseph Bastian; Alex Flitter; Nancy C Jao; Allison Carroll; Ravi Kalhan; Frank Leone; Brian Hitsman; Robert Schnoll Journal: Nicotine Tob Res Date: 2019-07-17 Impact factor: 4.244
Authors: Robert A Schnoll; Randi L Rothman; Dustin B Wielt; Caryn Lerman; Holly Pedri; Hao Wang; James Babb; Suzanne M Miller; Benjamin Movsas; Eric Sherman; John A Ridge; Michael Unger; Corey Langer; Melvyn Goldberg; Walter Scott; Jonathan Cheng Journal: Ann Behav Med Date: 2005-08
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Daniel F Heitjan; Alexandra E Shields; David A Asch; Caryn Lerman Journal: Ann Intern Med Date: 2010-02-02 Impact factor: 25.391
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: E R Gritz; C R Carr; D Rapkin; E Abemayor; L J Chang; W K Wong; T R Belin; T Calcaterra; K T Robbins; G Chonkich Journal: Cancer Epidemiol Biomarkers Prev Date: 1993 May-Jun Impact factor: 4.254
Authors: Jane Walker; Christian Holm Hansen; Paul Martin; Stefan Symeonides; Ravi Ramessur; Gordon Murray; Michael Sharpe Journal: Lancet Psychiatry Date: 2014-08-28 Impact factor: 27.083
Authors: Stephanie R Land; Benjamin A Toll; Carol M Moinpour; Sandra A Mitchell; Jamie S Ostroff; Dorothy K Hatsukami; Sonia A Duffy; Ellen R Gritz; Nancy A Rigotti; Thomas H Brandon; Sheila A Prindiville; Linda P Sarna; Robert A Schnoll; Roy S Herbst; Paul M Cinciripini; Scott J Leischow; Carolyn M Dresler; Michael C Fiore; Graham W Warren Journal: Clin Cancer Res Date: 2016-02-17 Impact factor: 12.531
Authors: Benjamin A Toll; Thomas H Brandon; Ellen R Gritz; Graham W Warren; Roy S Herbst Journal: Clin Cancer Res Date: 2013-04-09 Impact factor: 12.531
Authors: Allison J Carroll; Kristine Kim; Andrew Miele; Matthew Olonoff; Frank T Leone; Robert A Schnoll; Brian Hitsman Journal: Addict Behav Date: 2019-04-03 Impact factor: 3.913
Authors: Julia R May; Nancy C Jao; Kristen McCarter; Elizabeth Klass; Timothy Pearman; Frank Leone; Robert A Schnoll; Brian Hitsman Journal: Oncol Nurs Forum Date: 2021-01-04 Impact factor: 2.172
Authors: Rebecca L Ashare; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Ronald G Collman; E Paul Wileyto; Robert Schnoll Journal: Drug Alcohol Depend Date: 2019-05-07 Impact factor: 4.492
Authors: Elyse R Park; Giselle K Perez; Susan Regan; Alona Muzikansky; Douglas E Levy; Jennifer S Temel; Nancy A Rigotti; William F Pirl; Kelly E Irwin; Ann H Partridge; Mary E Cooley; Emily R Friedman; Julia Rabin; Colin Ponzani; Kelly A Hyland; Susan Holland; Sarah Borderud; Kim Sprunck; Diana Kwon; Lisa Peterson; Jacob Miller-Sobel; Irina Gonzalez; C Will Whitlock; Laura Malloy; Suhana de León-Sanchez; Maureen O'Brien; Jamie S Ostroff Journal: JAMA Date: 2020-10-13 Impact factor: 56.272
Authors: Joshua L Karelitz; Erin A McClure; Caitlin Wolford-Clevenger; Lauren R Pacek; Karen L Cropsey Journal: Drug Alcohol Depend Date: 2021-02-03 Impact factor: 4.492
Authors: Frank T Leone; Yuqing Zhang; Sarah Evers-Casey; A Eden Evins; Michelle N Eakin; Joelle Fathi; Kathleen Fennig; Patricia Folan; Panagis Galiatsatos; Hyma Gogineni; Stephen Kantrow; Hasmeena Kathuria; Thomas Lamphere; Enid Neptune; Manuel C Pacheco; Smita Pakhale; David Prezant; David P L Sachs; Benjamin Toll; Dona Upson; Dan Xiao; Luciane Cruz-Lopes; Izabela Fulone; Rachael L Murray; Kelly K O'Brien; Sureka Pavalagantharajah; Stephanie Ross; Yuan Zhang; Meng Zhu; Harold J Farber Journal: Am J Respir Crit Care Med Date: 2020-07-15 Impact factor: 21.405
Authors: Rukshar K Gobarani; Jenni Ilomäki; Stephen Wood; Michael J Abramson; Billie Bonevski; Johnson George Journal: Addiction Date: 2022-06-11 Impact factor: 7.256
Authors: Thulasee Jose; Joshua W Ohde; J Taylor Hays; Michael V Burke; David O Warner Journal: Int J Environ Res Public Health Date: 2020-06-06 Impact factor: 3.390
Authors: Jonathan B Bricker; Noreen L Watson; Jaimee L Heffner; Brianna Sullivan; Kristin Mull; Diana Kwon; Johann Lee Westmaas; Jamie Ostroff Journal: JMIR Form Res Date: 2020-01-17